Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;83(18):1709-1715.
doi: 10.1007/s40265-023-01964-8.

Momelotinib: First Approval

Affiliations
Review

Momelotinib: First Approval

Susan J Keam. Drugs. 2023 Dec.

Abstract

Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or high-risk MF, including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. This article summarizes the milestones in the development of momelotinib leading to this first approval for MF.

PubMed Disclaimer

Similar articles

Cited by

References

    1. GlaxoSmithKline. OJJAARA (momelotinib): US prescribing information 2023. https://ojjaara.com/ . Accessed 19 Sep 2023.
    1. Ikeda K, Ueda K. Gaining MOMENTUM against anaemic myelofibrosis. Lancet. 2023;401(10373):248–9. - DOI - PubMed
    1. Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954–70. - DOI - PubMed
    1. Bassiony S, Harrison CN, McLornan DP. Evaluating the safety, efficacy, and therapeutic potential of momelotinib in the treatment of intermediate/high-risk myelofibrosis: evidence to date. Ther Clin Risk Manag. 2020;16:889–901. - DOI - PubMed - PMC
    1. Verstovsek S, Chen CC, Egyed M, et al. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol. 2021;17(12):1449–58. - DOI - PubMed

Substances

LinkOut - more resources